There is no cost to you for this study (study drug, the labs, the visits), and you will be reimbursed $35.00 per completed study visit for transport costs. This is A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD). The study can last for up to 4 years: 35-day screening period, 2 drug-testing periods, and a 30-day follow-up call or visit.
Indication: PSA - Psoriatic Arthrtis
Protocol number: M15-554
Possible Stipend: $ 1015
Check back soon for more features!